TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A study published in Nature Communications links the gut-bacteria-produced molecule imidazole propionate (ImP) with Alzheimer’s-related biological markers and faster cognitive decline. Mouse experiments and human blood-sample analyses support the link, but do not establish that ImP causes Alzheimer’s or that lowering it would prevent or slow the disease.
Researchers report that imidazole propionate (ImP), a molecule produced by some gut bacteria, was linked to Alzheimer’s-related brain changes in mice and to faster cognitive decline among people whose blood samples were studied. The findings, published in Nature Communications, point to a possible research target but do not establish that ImP causes Alzheimer’s disease or that reducing it would prevent the illness.
The team, led by researchers at the University of Wisconsin-Madison, examined ImP because earlier research had found differences in gut microorganisms between people with Alzheimer’s disease and healthy individuals. In the new mouse experiments, ImP that reached the brain was associated with increased accumulation of abnormal beta-amyloid and tau proteins, which are major features associated with Alzheimer’s. The study did not show that the same experimental effects occur in people.
For the human analysis, researchers examined blood samples from nearly 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies through the Wisconsin Alzheimer’s Disease Research Center. Higher blood ImP concentrations were associated with biological markers linked to abnormal proteins and impaired neuron function. Participants with the highest ImP levels also showed faster decline on cognitive tests taken over time, according to the researchers.
The study also identified a genetic variation associated with substantially higher ImP levels; about 43% of participants carried it. The researchers suspect the variation may affect how efficiently the kidneys clear ImP from blood, but that explanation remains a hypothesis. The study received support from the Wisconsin Partnership Program, the National Institutes of Health and the U.S. Department of Agriculture, among other sources.
A Possible Target Beyond Diet
The findings give researchers a specific molecule to investigate in the relationship between gut microbes and brain health. If further work confirms that ImP contributes to disease processes, therapies designed to lower its levels could eventually offer a way to address a risk pathway distinct from simply changing food choices. That possibility is preliminary: the study does not test an ImP-lowering treatment or show that lowering the molecule changes dementia outcomes.
The researchers caution against treating histidine, the amino acid some gut bacteria use to produce ImP, as something to eliminate. Histidine is essential to human health and occurs in many foods, particularly protein-rich foods. Study leader Barbara Bendlin said broad dietary improvement might help overall health, but avoiding particular foods is not a straightforward way to control ImP. The immediate value is a research lead, not a dietary prescription or a clinical recommendation.
Products Worth Considering
Garmin Venu 3 Fitness Smartwatch, 45 mm, Black
Garmin Forerunner 570 GPS Running Smartwatch, 47mm, Aluminum, Black
Oura Ring 4 Smart Ring – Silver – Size 8
As an affiliate, we earn on qualifying purchases.
From Gut Microbes to ImP
Nearly a decade before this study, a team led by UW-Madison professors Barbara Bendlin and Federico Rey reported that the intestinal microbial mix differed between people with Alzheimer’s and healthy individuals. The researchers have since investigated how gut differences might relate to changes in the brain. ImP became a focus because certain intestinal bacteria produce it while using histidine for energy.
ImP levels vary among people. The research team says bacteria capable of producing it are present in many people, although they are not abundant in most. After production in the gut, ImP can enter the bloodstream and reach other parts of the body. Earlier research had linked the molecule to type 2 diabetes and coronary artery disease; this study adds evidence concerning brain-related markers and cognition, without proving a causal pathway in humans.
“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”
— Barbara Bendlin, professor of medicine at the University of Wisconsin-Madison
Cause and Treatment Remain Unproven
The human findings show associations, not proof that ImP causes Alzheimer’s, accelerates dementia, or is responsible for the cognitive changes observed. The mouse results offer experimental evidence of effects in animals, but do not establish that lowering ImP would produce a benefit in people. The report does not describe a clinical trial testing a treatment that reduces the molecule.
It is also unclear how much the genetic variation contributes to ImP levels through kidney clearance, whether other biological factors account for the association, and which people might benefit from a future intervention. The study’s human participants came from Wisconsin research cohorts; the supplied report does not establish whether results apply to broader populations. No dietary change or drug can be recommended on the basis of these findings alone.
Testing ImP as a Treatment Target
The next steps are to test the proposed biological pathway in further research and determine whether ImP can be safely and reliably reduced. Researchers would also need to clarify the role of the genetic variation and kidney clearance, and establish whether ImP levels predict changes in cognition beyond the associations reported here.
Any prevention claim would require studies showing that an intervention that lowers ImP also changes meaningful outcomes in people. Until such evidence is available, the finding remains a potential lead for Alzheimer’s research, not a proven prevention method. The study involved collaborators from the University of California, Los Angeles and the University of Gothenburg, alongside the Wisconsin researchers.
Key Questions
Does this study prove that ImP causes Alzheimer’s disease?
No. The researchers found associations between blood ImP levels and Alzheimer’s-related markers and cognitive decline in people. Mouse experiments linked ImP exposure with abnormal protein accumulation, but the findings do not prove that ImP causes Alzheimer’s in humans.
Should people avoid foods that contain histidine?
The study does not support avoiding histidine-rich foods. Histidine is an essential amino acid found in many foods, and researcher Barbara Bendlin said reducing particular foods is not a simple way to control ImP.
Could a medicine that lowers ImP prevent dementia?
That is a possibility proposed by the researchers, not an established treatment. The study did not test an ImP-lowering drug or show that reducing ImP prevents dementia or slows cognitive decline.
What was the human evidence based on?
Researchers analyzed blood samples and cognitive-test results from nearly 1,200 participants in Wisconsin Alzheimer’s research cohorts. Higher ImP levels were associated with relevant biological markers and faster cognitive decline over time.
Source: rss
